Assessment of a potential dopaminergic prodrug moiety in several ring systems.

  title={Assessment of a potential dopaminergic prodrug moiety in several ring systems.},
  author={Joseph Gerard Cannon and David C. Furlano and Russell G. Dushin and Y A Chang and Samuel R. Baird and L N Soliman and Jan R. Flynn and John Paul Long and Raj Bhatnagar},
  journal={Journal of medicinal chemistry},
  volume={29 10},
The ortho hydroxy/methyl, hydroxy/hydroxymethyl, hydroxy/formyl, and hydroxy/carboxy substitution patterns, some of which confer dopaminergic agonist effects upon 2-aminotetralin ring systems, have been incorporated into beta-phenethylamine, 2-aminoindan, and trans-octahydrobenzo[f]quinoline rings. Certain of the 2-aminoindan derivatives displayed pharmacologic properties consistent with their being dopaminergic agonists. The beta-phenethylamine derivative did not show any significant dopamine… 
Recent advances towards the discovery of dopamine receptor ligands
This review provides an overview of the recent patent literature during 2003 – 2005 on the development of therapeutic agents, mainly targeting the five dopamine receptors.
2-aminoindanes utilises comme ligands selectifs de la dopamine d3
Sont decrits des composes et leurs sels pharmaceutiquement acceptables pour traiter les troubles du systeme nerveux central associes a l'activite du recepteur de la dopamine D3. Ces composes ont la
Kurzmitteilungen: Synthesis and Biological Evaluation of 3‐(2‐Aminoethyl)pyrrole Derivatives Synthese und biologische Bewertung von 3‐(2‐Aminoethyl)pyrrol‐Derivaten
The ergolines are an important class of dopamine receptor agonists1), and the identification of their dopaminergic pharmacophore has been sought as a means of developing “purer” agonists related to
Reductive Aminations of Carbonyl Compounds with Borohydride and Borane Reducing Agents
Reductive amination is an important tool for synthetic organic chemists in the construction of carbon-nitrogen bonds. This reaction, also termed reductive alkylation, involves condensation of an
Cette invention concerne des tetralines d'utilite therapeutique ainsi que leurs sels d'addition acide pharmaceutiquement acceptables de formule (I) dans laquelle R, R1 et A sont definis dans la